Výsledky vyhledávání - "Hashemi, S M S"

Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)

Publikováno v: Illini, O, Fabikan, H, Swalduz, A, Krenbek, D, Vikstrom, A, Schumacher, M, Dudnik, E, Studnicka, M, Ohman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP) ', Journal of Thoracic Oncology, vol. 17, no. 9, pp. S460-S460 .
Journal of Thoracic Oncology, 17(9), S460-S460. International Association for the Study of Lung Cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3edf4f818230f06efbece638823d2977
https://research.vumc.nl/en/publications/257aeb33-e1d5-4456-afd1-4318a67e7361

Zobrazit plný text záznamu

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis

Publikováno v: Dafni, U; Soo, R A; Peters, S; Tsourti, Z; Zygoura, P; Vervita, K; Han, J-Y; De Castro, J; Coate, L; Früh, M; Hashemi, S M S; Nadal, E; Carcereny, E; Sala, M A; Bernabé, R; Provencio, M; Cuffe, S; Roschitzki-Voser, H; Ruepp, B; Rosell, R; ... (2022). Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open, 7(3), p. 100507. Elsevier 10.1016/j.esmoop.2022.100507
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J Y, de Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis ', ESMO OPEN, vol. 7, no. 3, 100507 . https://doi.org/10.1016/j.esmoop.2022.100507
ESMO OPEN, 7(3):100507. BMJ Publishing Group

BACKGROUND The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb1158fc2f612674302c02409c0a690
https://pubmed.ncbi.nlm.nih.gov/35696746

Zobrazit plný text záznamu

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Autor: Sooy, R. A. Han, J. -Y. Dafni, U. Cho, B. C. Yeo, C. M. and Nadal, E. Carcereny, E. de Castro, J. Sala, M. A. and Bernabe, R. Coate, L. Provencio Pulla, M. Campelo, R. Garcia and Cuffe, S. Hashemi, S. M. S. Fruh, M. Massuti, B. and Garcia-Sanchez, J. Domine, M. Majem, M. Sanchez-Torres, J. -M. Britschgi, C. Pless, M. Dimopoulou, G. and Roschitzki-Voser, H. Ruepp, B. Rosell, R. Stahel, R. A. and Peters, S. ETOP 10-16 BOOSTER Collaborators

Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::0fd242c68cafda7025ac62c44a663f8b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3034424

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial

Autor: Jebbink, M., De Langen, A. J., Monkhorst, K., Boelens, M. C., Van den Broek, D., Van der Noort, V., De Gooijer, C. J., Van der Wekken, A. J., Hendriks, L., Hashemi, S. M. S., Paats, M. S., Dingemans, A., Smit, E.

Publikováno v: Journal of Thoracic Oncology, 16(10), S891-S892. International Association for the Study of Lung Cancer
Jebbink, M, De Langen, A J, Monkhorst, K, Boelens, M C, Van den Broek, D, Van der Noort, V, De Gooijer, C J, Van der Wekken, A J, Hendriks, L, Hashemi, S M S, Paats, M S, Dingemans, A & Smit, E 2021, ' T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial ', Journal of Thoracic Oncology, vol. 16, no. 10, pp. S891-S892 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::9eaf69343ee92f118deb9c35ab89795a
https://research.vumc.nl/en/publications/f4c3ff07-cae6-48ae-a63b-42e5409f549d

Zobrazit plný text záznamu

Treatment Recommendations for Stage III NSCLC by 3 Dutch Multidisciplinary Tumor Boards Prior To, and Following the PACIFIC Trial

Publikováno v: Journal of Thoracic Oncology, 16(10), S904-S904. International Association for the Study of Lung Cancer
Ronden, M, Bahce, I, Claessens, N, Barlo, N, Dahele, M, Daniels, J, Tissing-Tan, C, Hekma, E, Hashemi, S M S, Van Der Wel, A, Spoelstra, F, Verbakel, W, Tiemessen, M, Van Laren, M, Becker, A, Tarasevych, S, Haasbeek, C, Van Den Brink, K M, Dickhoff, C & Senan, S 2021, ' Treatment Recommendations for Stage III NSCLC by 3 Dutch Multidisciplinary Tumor Boards Prior To, and Following the PACIFIC Trial ', Journal of Thoracic Oncology, vol. 16, no. 10, pp. S904-S904 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::26a65d155965291bf15b11c81b644409
https://research.vumc.nl/en/publications/e93e4e09-5395-419e-b1b8-d3ad9e0a3f26

Zobrazit plný text záznamu

Trimodality Therapy Protocol in 144 Superior Sulcus Patients: Good Results Even for Extended Resections and Indications

Autor: Paul, M., Winkelman, J., Dickhoff, C., Heineman, D., Hashemi, S. M. S., Dahele, M., Unal, S., Zandbergen, H., Koolen, B., Braun, J.

Publikováno v: Journal of Thoracic Oncology, 16(10), S1074-S1074. International Association for the Study of Lung Cancer
Paul, M, Winkelman, J, Dickhoff, C, Heineman, D, Hashemi, S M S, Dahele, M, Unal, S, Zandbergen, H, Koolen, B & Braun, J 2021, ' Trimodality Therapy Protocol in 144 Superior Sulcus Patients: Good Results Even for Extended Resections and Indications ', Journal of Thoracic Oncology, vol. 16, no. 10, pp. S1074-S1074 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5f873e96e6cb00ddfa5c0024966a2f81
https://research.vumc.nl/en/publications/c4d5f85c-caa1-4d48-a8b7-290a9f2925c9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání